Chargement en cours...
Efficacy and Safety of Alemtuzumab in Multiple Sclerosis and Impact on Nursing Role
Alemtuzumab, a humanized monoclonal antibody, has shown efficacy for relapsing-remitting multiple sclerosis (MS) in phase 2 and phase 3 trials. Compared with subcutaneous interferon beta-1a, alemtuzumab significantly reduced the risk for accumulation of disability and the rate of relapse, and improv...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
The Consortium of Multiple Sclerosis Centers
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3883016/ https://ncbi.nlm.nih.gov/pubmed/24453779 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2013-004 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|